ACN Newswire
SHANGHAI, Nov 30, 2024 – (ACN Newswire) – Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC).The SENSITIZE study was initiated by Professor Juliana Chan…
Read More
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC
Michele Schroeder
05:21
SHANGHAI, Nov 30, 2024 – (ACN Newswire) – Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC).The SENSITIZE study was initiated by Professor Juliana
